Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :703
Small font sizeDefault font sizeIncrease font size
Read this article

 


    Article Cited by others

ORIGINAL ARTICLE

Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer

Galal K M, Khaled Z, Mourad Abdel Monem M

Year : 2011| Volume: 48| Issue : 1 | Page no: 47-54

   This article has been cited by
 
1 Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
Miaomiao Gou,Haiyan Si,Yong Zhang,Niansong Qian,Zhikuan Wang,Weiwei Shi,Guanghai Dai
Scientific Reports. 2018; 8(1)
[Pubmed]  [Google Scholar] [DOI]
2 Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
James Mattina,Benjamin Carlisle,Yasmina Hachem,Dean Fergusson,Jonathan Kimmelman,Lisa Bero
PLOS Biology. 2017; 15(2): e2000487
[Pubmed]  [Google Scholar] [DOI]
3 Risk of Hypertension With Sorafenib Use in Patients With Cancer
XiongWen Yang,Xiong Pan,Xiaoshu Cheng,YuKang Kuang,YingZhang Cheng
American Journal of Therapeutics. 2017; 24(1): e81
[Pubmed]  [Google Scholar] [DOI]
4 Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
Aviad Zick,Tamar Peretz,Michal Lotem,Ayala Hubert,Daniela Katz,Mark Temper,Yakir Rottenberg,Beatrice Uziely,Hovav Nechushtan,Amichai Meirovitz,Amir Sonnenblick,Eli Sapir,David Edelman,Yael Goldberg,Alexander Lossos,Shai Rosenberg,Iris Fried,Ruth Finklstein,Eli Pikarsky,Hanoch Goldshmidt
Medicine. 2017; 96(20): e6931
[Pubmed]  [Google Scholar] [DOI]
5 Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer
Veena A. Thomas,Joseph P. Balthasar
The AAPS Journal. 2016; 18(4): 923
[Pubmed]  [Google Scholar] [DOI]
6 B-type proto-oncogene-mutated tumors of colon cancer
Sally Temraz,Raafat Alameddine,Ali Shamseddine
Current Opinion in Oncology. 2015; 27(3): 276
[Pubmed]  [Google Scholar] [DOI]
7 Combined therapeutic efficacy of 188Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells
YA-JEN CHANG,WEI-HSIN HSU,CHIH-HSIEN CHANG,KENG-LI LAN,GANN TING,TE-WEI LEE
Molecular and Clinical Oncology. 2014; 2(3): 380
[Pubmed]  [Google Scholar] [DOI]
8 What Could Nintedanib (BIBF 1120), a Triple Inhibitor of VEGFR, PDGFR, and FGFR, Add to the Current Treatment Options for Patients with Metastatic Colorectal Cancer?
Jaume Capdevila,Alfredo Carrato,Josep Tabernero,Enrique Grande
Critical Reviews in Oncology/Hematology. 2014;
[Pubmed]  [Google Scholar] [DOI]
9 result 1 Document Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
Authors of Document Connolly, K., Brungs, D., Szeto, E., Epstein, R.J.
Current Oncology. 2014;
[Pubmed]  [Google Scholar]
10 result 6 Document Gemeinsames Auftreten von 4 Kolontumoren | [Common appearance of 4 colon tumors]
Meissner, C., Teichmann, M., Meissner, G.
Chirurgische Praxis. 2013;
[Pubmed]  [Google Scholar]
11 result 2 Document Risk of treatment-related mortality with sorafenib in patients with cancer
Zhang, X.-J., Zhang, T.-Y., Yu, F.-F., (...), Wei, L.-X., He, J.
Source of the Document Asian Pacific Journal of Cancer Prevention. 2013;
[Pubmed]  [Google Scholar]
12 result 3 Document Risk of hypertension in cancer patients treated with sorafenib: An updated systematic review and meta-analysis
Authors of Document Funakoshi, T., Latif, A., Galsky, M.D.
Journal of Human Hypertension. 2013;
[Pubmed]  [Google Scholar]
13 result 4 Document Personalizing colon cancer therapeutics: Targeting old and new mechanisms of action
Authors of Document Kline, C.L.B., El-Deiry, W.S.
Source of the Document Pharmaceuticals. 2013;
[Pubmed]  [Google Scholar]
14 Anti-metastatic treatment in colorectal cancer: Targeting signaling pathways
Lemos, C. and Sack, U. and Schmid, F. and Juneja, M. and Stein, U.
Current Pharmaceutical Design. 2013; 19(5): 841-863
[Pubmed]  [Google Scholar]
15 Novel antineoplastics targeting genetic changes in colorectal cancer
Joudeh, J. and Allen, J.E. and Das, A. and Prabhu, V. and Farbaniec, M. and Adler, J. and El-Deiry, W.S.
Advances in Experimental Medicine and Biology. 2013; 779: 1-34
[Pubmed]  [Google Scholar]
16 Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
T Funakoshi,A Latif,M D Galsky
Journal of Human Hypertension. 2013; 27(10): 601
[Pubmed]  [Google Scholar] [DOI]
17 Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
Mhd Yaser Al-Marrawi,Bikramajit Singh Saroya,Matthew C Brennan,Zhaohai Yang,Thomas M Dykes,Wafik S El-Deiry
Cancer Biology & Therapy. 2013; 14(8): 703
[Pubmed]  [Google Scholar] [DOI]
18 Risk of Treatment-related Mortality with Sorafenib in Patients with Cancer
Xin-Ji Zhang,Tian-Yi Zhang,Fei-Fei Yu,Xin Wei,Ye-Sheng Li,Feng Xu,Li-Xin Wei,Jia He
Asian Pacific Journal of Cancer Prevention. 2013; 14(11): 6681
[Pubmed]  [Google Scholar] [DOI]
19 Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
Christina Kline,Wafik El-Deiry
Pharmaceuticals. 2013; 6(8): 988
[Pubmed]  [Google Scholar] [DOI]
20 Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
Amartej Merla,Sanjay Goel
Chemotherapy Research and Practice. 2012; 2012: 1
[Pubmed]  [Google Scholar] [DOI]

 

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow